Serotonin 5-HT2B receptors are required for 3,4- methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro

Journal of Neuroscience

Volumn 28, Issue 11, 2008, Pages 2933-2940

  Doly, Stéphane ^a,b   Valjent, Emmanuel ^a,b   Setola, Vincent ^a,b   Callebert, Jacques ^c,d   Hervé, Denis ^a,b   Launay, Jean Marie ^c,d   Maroteaux, Luc ^a,b,e  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d Inst Federatif de Rech 49   (France)

^e INSTITUT DU FER À MOULIN   (France)

Author keywords

5 HT2B; Behavior; MDMA; Microdialysis; Serotonin release; Synaptosomes

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; POSTSYNAPTIC RECEPTOR; PRESYNAPTIC RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HYPERACTIVITY; IN SITU HYBRIDIZATION; LOCOMOTION; MALE; MESENCEPHALON; MICRODIALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTONIN RELEASE; SYNAPTOSOME; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; HYPERKINESIA; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; PROTEIN BINDING; SECRETION;

ANIMALS; FEMALE; HYPERKINESIS; MALE; MICE; MICE, MUTANT STRAINS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROTEIN BINDING; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 40849142489     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5723-07.2008     Document Type: Article

References (40)

1. Adell A, Celada P, Abellan MT, Artigas F (2002) Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res Brain Res Rev 39:154-180.
2. Bankson MG, Cunningham KA (2001) 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297:846-852.
3. Bankson MG, Yamamoto BK (2004) Serotonin-GABA interactions modulate MDMA-induced mesolimbic dopamine release. J Neurochem 91:852-859.
4. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159-163.
5. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, Lesch KP (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol 53:649-655.
6. Blakely RD, Ramamoorthy S, Schroeter S, Qian Y, Apparsundaram S, Galli A, DeFelice LJ (1998) Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry 44:169-178.
7. Bonaventure P, Guo H, Tian B, Liu X, Bittner A, Roland B, Salunga R, Ma XJ, Kamme F, Meurers B, Bakker M, Jurzak M, Leysen JE, Erlander MG (2002) Nuclei and subnuclei gene expression profiling in mammalian brain. Brain Res 943:38-47.
8. Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, Van Natta K, Chang LK, Pulido-Rios T, Webber A, Leung E, Eglen RM, Martin GR (1999) RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharmacol 127:1075-1082.
9. Callebert J, Esteve JM, Herve P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L (2006) Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice. J Pharmacol Exp Ther 317:724-731.
10. Choi DS, Maroteaux L (1996) Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain. FEBS Lett 391:45-51.
11. Crespi D, Mennini T, Gobbi M (1997) Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121:1735-1743.
12. 3 receptors. J Neurosci 18:6528-6538.
13. Duxon MS, Flanigan TP, Reavley AC, Baxter GS, Blackburn TP, Fone KC (1997) Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience 76:323-329.
14. Fog JU, Khoshbouei H, Holy M, Owens WA, Vaegter CB, Sen N, Nikandrova Y, Bowton E, McMahon DG, Colbran RJ, Daws LC, Sitte HH, Javitch JA, Galli A, Gether U (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51:417-429.
15. Gray EG, Whittaker VP (1962) The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. J Anat 96:79-88.
16. Gudelsky GA, Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66:243-249.
17. Gunther S, Maroteaux L, Schwarzacher SW (2006) Endogenous 5-HT2B receptor activation regulates neonatal respiratory activity in vitro. J Neurobiol 66:949-961.
18. Kankaanpaa A, Meririnne E, Lillsunde P, Seppala T (1998) The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 59:1003-1009.
19. Kennett GA, Trail B, Bright F (1998) Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated. Neuropharmacology 37:1603-1610.
20. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, Galli A, Javitch JA (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2:E78.
21. Launay JM, Bondoux D, Oset-Gasque MJ, Emami S, Mutel V, Haimart M, Gespach C (1994) Increase of human platelet serotonin uptake by atypical histamine receptors. Am J Physiol 266:R526-R536.
22. Launay JM, Schneider B, Loric S, Da Prada M, Kellermann O (2006) Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J 20:1843-1854.
23. Lin Z, Walther D, Yu XY, Drgon T, Uhl GR (2004) The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse. Pharmacogenetics 14:805-811.
24. Manivet P, Mouillet-Richard S, Callebert J, Nebigil CG, Maroteaux L, Hosoda S, Kellermann O, Launay JM (2000) PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor. J Biol Chem 275:9324-9331.
25. McCreary AC, Cunningham KA (1999) Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacology 20:556-564.
26. Miller KJ, Hoffman BJ (1994) Adenosine A3 receptors regulate serotonin transport via nitric oxide and cGMP. J Biol Chem 269:27351-27356.
27. Mortensen OV, Amara SG (2003) Dynamic regulation of the dopamine transporter. Eur J Pharmacol 479:159-170.
28. Morton J (2005) Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 5:79-86.
29. Muller CP, Carey RJ, Huston JP, Souza Silva MA (2007) Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors. Prog Neurobiol 81:133-178.
30. Nebigil CG, Choi DS, Dierich A, Hickel P, Le Meur M, Messaddeq N, Launay JM, Maroteaux L (2000) Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA 97:9508-9513.
31. Nestler EJ (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8:1445-1449.
32. 2A receptors. J Neurosci 25:11231-11238.
33. Ramamoorthy S, Samuvel DJ, Buck ER, Rudnick G, Jayanthi LD (2007) Phosphorylation of threonine residue 276 is required for acute regulation of serotonin transporter by cyclic GMP. J Biol Chem 282:11639-11647.
34. Rudnick G, Wall SC (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89:1817-1821.
35. Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H (1996) Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosci 8:959-967.
36. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229.
37. Sharp T, Boothman L, Raley J, Queree P (2007) Important messages in the "post": recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci 28:629-636.
38. Torres GE, Gainetdinov RR, Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4:13-25.
39. Trigo JM, Renoir T, Lanfumey L, Hamon M, Lesch KP, Robledo P, Maldonado R (2007) 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol Psychiatry 62:669-679.
40. Zhu CB, Steiner JA, Munn JL, Daws LC, Hewlett WA, Blakely RD (2007) Rapid stimulation of presynaptic serotonin transport by a3 adenosine receptors. J Pharmacol Exp Ther 322:332-340.